TOFA Acetyl-CoA carboxylase inhibitor

Cat.No.S6690

TOFA is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). Inside the cell, this compound is converted to TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA), exerting an allosteric inhibition on ACCA. It blocks fatty acid synthesis and induces cell death in a dose-dependent manner.
TOFA Acetyl-CoA carboxylase inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 324.45

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 324.45 Formula

C19H32O4

 

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 54857-86-2 -- Storage of Stock Solutions

Synonyms 5-(Tetradecyloxy)-2-furoic acid, RMI14514; MDL14514 Smiles CCCCCCCCCCCCCCOC1=CC=C(O1)C(=O)O

Solubility

In vitro
Batch:

DMSO : 4 mg/mL (12.32 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
ACCA [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05728008 Completed
Ulcerative Colitis
IRCCS San Raffaele
April 5 2022 --
NCT04721808 Completed
Arthritis Rheumatoid
Pfizer
January 22 2021 --
NCT03288324 Completed
Cutaneous Lupus|Systemic Lupus Erythematosus
Children''s Hospital Medical Center Cincinnati|Pfizer
August 23 2017 Phase 1|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.